6 assets in Non-Cutaneous Melanoma

Therapeutic assets addressing Non-Cutaneous Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Non-Cutaneous Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P3	BB (65)
Pembrolizumab Non-Cutaneous Melanoma	National Cancer Institute (NCI)	P3	B (60)
Interferon Alfa-2B Non-Cutaneous Melanoma	National Cancer Institute (NCI)	P3	B (59)
Ipilimumab Non-Cutaneous Melanoma	National Cancer Institute (NCI)	P3	B (59)
Fludarabine Non-Cutaneous Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Tbio-4101 Non-Cutaneous Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)